Navigation Links
Rifampin: Latent TB treatment saves time money and lives
Date:5/20/2008

ATS 2008, TORONTOA new way to treat patients with latent tuberculosis (TB), who are infected with TB but without symptoms, can effectively treat it in less than half the time and at a lower cost than the current standard treatment, according to researchers who conducted a multi-center, randomized controlled trial. The results will be presented at the American Thoracic Societys 2008 International Conference in Toronto on Tuesday, May 20.

We found that using a therapy of four months of Rifampin instead of the current nine months of Isoniazid costs significantly less for the healthcare system, said lead analyst, Anne Aspler, M.Sc., of the Respiratory Epidemiology & Clinical Research Unit at McGill Universitys Montreal Chest Institute. Overall, Rifampin costs about $484 less per patient treated, which, if we assume that four months of Rifampin has at least equal efficacy to nine months of Isoniazid, represents an added savings to the health system of more than $10,000 per patient prevented from developing TB disease. And because of improvements in compliance, we are actually preventing more cases. This treatment can save money as well as lives.

At present, two billion people are believed to have latent or dormant TB. Of those infected, eight to nine million will develop TB each year, of whom 1.6 million will die. This is one of the most pressing public health crises in our modern world, said Ms. Aspler.

Rifampin is offered in developing countries, where TB presents the greatest burden, at a subsidized cost through the Global Drug Facility of the World Health Organization. In addition to the cost savings, therapy with Rifampin has the advantage of increased compliance.

While Isoniazid therapy is 90 percent effective for those who complete it, in reality, fewer than 50 percent do, Ms. Aspler explained. The high attrition rate can have serious public heath effects, not only for the patients who fail to complete therapy, but also for the individuals they may later infect.

According to previous research and program experience in Maryland and New Jersey, a four-month treatment has been shown to improve compliance by 20 to 25 percent. In addition to better completion rates, a four-month course of Rifampin offers the advantages of fewer adverse reactions (fewer serious side effects such as hepatotoxicity or liver damage), and lower costs.

The next step in research is a major Phase III clinical trial of efficacyideally in HIV-infected and non-infected patients and in low-income settings where tuberculosis is the leading cause of death in people living with HIV, said Ms. Aspler.


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. New chemical can kill latent tuberculosis bacteria
2. New treatment gives hope for pulmonary fibrosis patients
3. Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S.
4. Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa
5. Mapping of prostate cancer genes opens the door to new treatments
6. Many Diabetics Dont Get Necessary Blood Pressure Treatment
7. MR imaging accurately determines prostate cancer treatment failure
8. Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment
9. Old antibiotic may find new life as a stroke treatment
10. Radiofrequency ablation is effective treatment for dysplasia in Barretts esophagus
11. New Hair Loss Treatment Proves Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... Pa. , June 23, 2016 The ... in an outpatient dialysis facility.  Treatments are usually 3 ... 6 hours per visit, including travel time, equipment preparation ... a patient, but especially grueling for patients who are ... of a skilled nursing and rehabilitation centers for some ...
Breaking Medicine Technology: